Condition: Retinal Disease · Macular Degeneration · Age-Related Macular Degeneration · Sponsor: Eyestem Research Pvt. Ltd.
The goal of this clinical study is to evaluate the safety and efficacy of novel stem cell formulation in patients having Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (d-AMD). The main questions it aims to answer are: * Safety and tolerability of the novel stem cell formulation * Potential efficacy of the novel stem cell formulation Participants will receive a single subretinal injection in their study eye and followed up for safety. This is an India only study and the product is developed indigenously.
This description comes directly from the study's public registry record.
Dr Jogin Desai, MBBS · +91 7676235515 · jogin.desai@eyestem.com
Dr Rajani Battu, MBBS,MS,DNB,FRCS(Edin),PhD · +91 7676235515 · rajani.battu@eyestem.com
Always discuss trial participation with your own doctor first.
| Shri Ganapati Netralaya | Jālna, Maharashtra, India | Recruiting |
| All India Institute of Medical Sciences | Delhi, New Delhi, India | Recruiting |
| L V Prasad Eye Institute | Hyderabad, Telangana, India | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06394232